Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: A meta-analysis of randomized controlled trials

Integrative Cancer Therapies

Volumn 4, Issue 3, 2005, Pages 219-229

  Shu, Xiaojuan ^a,c   McCulloch, Michael ^a,b   Xiao, Hang ^c   Broffman, Michael ^a   Gao, Jin ^b  

^a Pine Street Foundation ^*  (United States)

^b INSTITUTE OF BIOPHYSICS   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Chinese herbal medicine; Hepatocellular carcinoma (HCC); Quasi randomized, controlled trials (quasi RCTs); Randomized, controlled trials (RCTs); Survival; Tumor response (TR)

Indexed keywords

ANTINEOPLASTIC AGENT; BRUCEA JAVANICA OIL; BU GAN RUAN JIAN TANG; CARBOPLATIN; CHINESE DRUG; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FU ZHENG HUA JI JIE DU FANG; FU ZHENG JIE DU TANG; FU ZHENG XIAO LIU HE JI; FU ZHENG YI LIU TANG; GAN AI JIAN JI; GAN AI YI HAO; GAN KANG CHONG JI; GE XIA ZHU YU TANG; GELATIN SPONGE; HERBACEOUS AGENT; HU GAN RUAN JIAN FANG; HUA CHAN SU; IODINATED POPPYSEED OIL; IOFENDYLATE; IRINOTECAN; LIU JUN ZI TANG; MITOMYCIN C; PEI YUAN GU BEN KANG AI JIAO NANG; PING XIAO JIAO NANG; PIRARUBICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHINESE HERB; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HERBAL MEDICINE; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

CARCINOMA, HEPATOCELLULAR; DRUGS, CHINESE HERBAL; HUMANS; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL; TREATMENT OUTCOME;

EID: 23844454022     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735405279927     Document Type: Article

References (43)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
2. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271-285.
3. Llovet JM, Bustamante J, Castells A. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62-67.
4. Chan ES, Chow PK, Tai B, Machin D, Soo K. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev. 2000(2):CD001199.
5. Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol. 2004;7:431-441.
6. De Maio E, Fiore F, Daniele B, et al. Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature. Crit Rev Oncol Hematol. 2003;46:285-295.
7. Geschwind JF, Ramsey DE, Choti MA, Thuluvath PJ, Huncharek MS. Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am J Clin Oncol. 2003;26:344-349.
8. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442.
9. Mathurin P, Raynard B, Dharancy S, et al. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma. Aliment Pharmacol Ther. 2003;17:1247-1261.
10. Berlin JA. Does blinding of readers affect the results of metaanalyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350:185-186.
11. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Vol offset publication no. 40. Geneva, Switzerland: World Health Organization; 1979.
12. Kountouras J, Zavos C, Chatzopoulos D, Zavos N, Boura P, Safioleas M. Locoregional immunochemotherapy in primary and metastatic liver disease: meta-analysis and review of literature. Hepatogastroenterology. 2003;50:1506-1510.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
14. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
15. Clark HD, Wells GA, Huet C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999;20:448-452.
16. Sun ZJ, Pan CE, Wang GJ. Clinical observation of Hua Chan Su combined with TAGE in the treatment of hepatocellular carcinoma. Zhong Liu Fang Zhi Yan Jiu. 2002;29:67-68.
17. Wu HM, Zhu DZ, Ling CQ, Chen Z. Clinical observation of hepatic artery intubation with Hua Chan Su infusion chemotherapy in treatment of liver cancer. Liaoning Journal of Traditional Chinese Medicine. 2000;27:127-128.
18. Hewitt C, Hahn S, Torgerson DJ, Watson J, Bland JM. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ. 2005;330:1057-1058.
19. Williams DH, Davis CE. Reporting of assignment methods in clinical trials. Control Clin Trials. 1994;15:294-298.
20. Cao MR, Tang HL. Observation of the effectiveness of Ai Di Zhu She Ye combined with hepatic artery infusion chemotherapy in the treatment of mid- and late-stage hepatocellular carcinoma. Zhong Guo Zhong Xi Yi Jie He Za Zhi. 2003;23:713-714.
21. Chen C, Zhou JG, Huang HC, Ruan SH, Zhang QS. Hepatic artery lipiodol infusion chemotherapy combined with Pei Yuan Gu Ben Kang Ai Jiao Nang in the treatment of 42 cases of mid- and late-stage hepatocellular carcinoma. Zhong Xi Yi Jie He Gan Bing Za Zhi. 2001;11:183-184.
22. Feng J. Chinese medicine and interventional therapy in the treatment of 35 cases of hepatocellular carcinoma. Guang Xi Zhong Yi Xue Yuan Xue Bao. 2002;5:51-52.
23. Gao P. Clinical study of Gan Ai Jian Ji combined with hepatic artery infusion chemoembolization in the treatment of hepatocellular carcinoma. Zhongguo Yi Yao Xue Bao. 2004;19:28-30.
24. Jia YS, Wu SQ, Qin ZQ, Lu LQ. Clinical analysis of Ya Dan Zi oil combined with interventional chemotherapy in treatment of primary hepatocellular carcinoma. Zhong Guo Zhong Yao Za Zhi. 2003;28:683-684.
25. Li J, Sun GZ, Pu BK, Chen CH, Song L. Clinical study of Gan Kang Chong Ji combined with hepatic artery interventional chemotherapy in the treatment of hepatocellular carcinoma. Yi Xue Li Lun Yu Shi Jian. 1998;11:341-343.
26. Li JC. Clinical study of Chinese medicine differential diagnosis combined with interventional therapy in the treatment of hepatocellular carcinoma. Guang Dong Yi Xue. 2001;22:263-264.
27. Li W, Li XL. Clinical study of Fu Zheng Yi Liu Tang in reducing toxicity and increasing effectiveness of chemotherapy in mid- and late-stage primary hepatocellular carcinomachemotherapy. Zhong Guo Zhong Yi Yao Xin Xi Za Zhi. 2001;8:52-53.
28. Liu XL, Zhu XQ. Clinical study in Yanshu in the treatment of hepatocellular carcinoma. Journal of Ningxia Medical College. 2002;24:105-106.
29. Shao ZX, Chen ZG, Yin XE, et al. Clinical observation of hepatic artery infusion chemotherapy combined with Chinese medicine Gan Ai I and II in the treatment of mid- and late-stage hepatocellular carcinoma. Zhong Guo Zhong Xi Yi Jie He Za Zhi. 2001;21:168-170.
30. Tian HQ, Liang GW, Tao Y, Huang ZQ, Yu SY, Ye WY. Clinical study of Chinese medicine combined with interventional therapy in the treatment of hepatocellular carcinoma. Henan Zhong Yi Yao Xue Kan. 2001;16:47-48.
31. Wang HZ. Clinical study of immune and Chinese medicine in post-treatment of liver cancer with infusion chemotherapy. Zhong Guo Zhong Xi Yi Jie He Za Zhi. 1998;18:411-413.
32. Wang ZX, Wu XH, Chen SQ. Fu Zheng Hua Ji Jie Du Fang and hepatic artery infusion chemotherapy in treatment of primary hepatocellular carcinoma. Henan Traditional Chinese Medicine. 2001;21:48-49.
33. Wu JX. Observation of long-term effectiveness of Yi Guan Jian Jia Wei combined with TACE in the treatment of hepatocellular carcinoma. Zhejiang Zhong Xi Yi Jie He Za Zhi. 1999;9:100-101.
34. Wu WG, Guo WJ, Lin JH. Ping Xiao capsule combined with hepatic artery infusion in the treatment of 25 cases of primary hepatocellular carcinoma. Zhong Xi Yi Jie He Gan Bing Za Zhi. 2001;11:50-51.
35. Wu XD, Wang YD, Liu SM, Wu ZS, Ye AN. Observation of Hu Gan Ruan Jian Fang in increasing effectiveness and reducing toxicity of hepatic artery chemoembolization in stage II and III hepatocellular carcinoma. Zhong Xi Yi Jie He Gan Bing Za Zhi. 2002;12:43-44.
36. Xie XR, Li JK, Zhan GQ. Ruan Gan Jian combined with chemotherapy in the treatment of 42 cases of mid- and late-stage hepatocellular carcinoma. Zhong Xi Yi Jie He Gan Bing Za Zhi. 2004;14:110-111.
37. Yu Y. Observations of the effect of hepatic artery chemoembolization combined with Chinese medicine in the treatment of mid- and late-stage hepatocellular carcinoma. Xian Dai Zhen Duan Yu Zhi Liao. 2002;13:1-3.
38. Zhang QZ, Zhang CL. Hepatic artery intubation embedding drug pump combined with Chinese medicine in the treatment of 30 cases of mid- and late-stage primary hepatocellular carcinoma. Practical Journal of Integrating Chinese With Modern Medicine. 1998;11:242.
39. Zhang SY, Geng NZ, Liu YE, Jiang W, Jiang LF. Clinical study of hepatic artery infusion chemotherapy combined with AC-III Zhu She Ye in the treatment of hepatocellular carcinoma. Information on Traditional Chinese Medicine. 1996(4):29-31.
40. Zhang YH. Clinical study of anti-tumor effect of Bu Gan Ruan Jian Tang. Hubei Zhong Yi Za Zhi. 1998;20(1):21-22.
41. Zhou BG, Sun JZ, Jing SH, Fan YZ, Huang YN. Observation of combined Chinese and Western medicine in the treatment of 26 cases of mid- and late-stage hepatocellular carcinoma. Xin Zhong Yi. 2002;34:37-38.
42. Zhou XY, Wu XD, Zuo X, Ge R, Xue YB. Clinical research of TACE combined with Chinese medicine in the treatment of 118 cases of mid- and late-stage hepatocellular carcinoma. Jiangsu Zhong Yi Yao. 2002;23:15-17.
43. Zhou YF, Jiao ZH, Song MM, et al. Fu Zheng Xiao Liu He Ji combined with chemotherapy in the treatment of 15 cases of primary hepatocellular carcinoma. Shandong Zhong Yi Yao Da Xue Xue Bao. 1999;23:123-125.